Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.
Type:
Grant
Filed:
September 21, 2016
Date of Patent:
March 26, 2019
Assignee:
Bracco S.P.A.
Inventors:
Livio Cavalieri, Giovanni Rivolta, Fulvia Vella
Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.
Type:
Application
Filed:
September 21, 2016
Publication date:
January 12, 2017
Applicant:
Bracco S.P.A.
Inventors:
Livio Cavalieri, Giovanni Rivolta, Fulvia Vella
Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.
Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.
Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.
Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.
Abstract: The involvement of intestinal microbiota in the initiation and perpetuation of inflammatory bowel disease is widely accepted. To reestablish the homeostasis of the gut the use of probiotics has been proposed, with however, limited clinical benefit. This invention relates to an assay based on the modulation of the immunological activity in DCs (dendritic cells) by probiotic strains, in particular L. paracasei and their use in protecting against inflammatory bowel and liver diseases.
Type:
Application
Filed:
July 20, 2010
Publication date:
April 12, 2012
Applicant:
BRACCO S.P.A.
Inventors:
Maria Rescigno, Carmelina Loguercio, Enzo Grossi
Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.
Abstract: A method for the laboratory determination of prosthetic infections is described. This method, performed on biological fluids isolated from patients, is based on the detection of antibodies specific for the polysaccharides produced by bacteria colonizing prosthetic devices.
Type:
Grant
Filed:
May 1, 2002
Date of Patent:
October 5, 2010
Assignee:
BRACCO S.p.A.
Inventors:
Maria Cristina Thaller, Gianmaria Rossolini, Laura Selan, Claudio Passariello
Abstract: The present invention is directed to ceramide analog compounds of general formula (I) the process for their preparation and use for the preparation of pharmaceutical formulations for the treatment of tumors
Type:
Grant
Filed:
August 17, 2004
Date of Patent:
May 8, 2007
Assignee:
Bracco S.p.A.
Inventors:
Bruno Macchia, Aldo Balsamo, Marco Macchia, Mario Del Tacca, Romano Danesi
Abstract: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations thereof.
Abstract: The present invention is directed to ceramide analog compounds of general formula (I) the process for their preparation and use for the preparation of pharmaceutical formulations for the treatment of tumors.
Type:
Grant
Filed:
July 21, 2000
Date of Patent:
October 18, 2005
Assignee:
Bracco S.p.A.
Inventors:
Bruno Macchia, Aldo Balsamo, Marco Macchia, Mario Del Tacca, Romano Danesi
Abstract: Compounds able to chelate bi- and trivalent paramagnetic metal ions, their chelated complexes with these metal ions and physiologically compatible salts thereof and therein magnetic resonance imaging.
Type:
Grant
Filed:
September 24, 2001
Date of Patent:
January 21, 2003
Assignee:
Bracco S.p.A.
Inventors:
Maurizio Franzini, Andrea Beltrami, Luisella Calabi, Alessandro Maiocchi, Mario Virtuani, Pier Lucio Anelli, Kondareddiar Ramalingam, Ramachandran S. Ranganathan
Abstract: A method for the laboratory determination of prosthetic infections is described. This method, performed on biological fluids isolated from patients, is based on the detection of antibodies specific for the polysaccharides produced by bacteria colonizing prosthetic devices.
Type:
Application
Filed:
May 1, 2002
Publication date:
December 26, 2002
Applicant:
Bracco S.p.A.
Inventors:
Maria Cristina Thaller, Gianmaria Rossolini, Laura Selan, Claudio Passariello
Abstract: A method for Magnetic Resonance Imaging (MRI) of changes in neurotransmitter and neuroreceptor activity as a metabolic response to diagnostic challenge or therapeutic treatment in a patient with suspected or already diagnosed mental illnesses of psychiatric, neurodegnerative or neurological nature, by (a) administering to a patient a drug eliciting an MRI detectable hemodynamic response; (b) administering to the patient an MRI contrast agent with high magnetic susceptibility, and then (c) measuring, in a spatially and temporally resolved manner, relative Cerebral Blood Volume (rCBV) changes associated to neuronal activation using T2- or T2*-weighted MRI scans at the equilibrium distribution of said contrast agent.
Type:
Grant
Filed:
April 7, 1999
Date of Patent:
November 20, 2001
Assignee:
Bracco S.p.A.
Inventors:
Bruce G. Jenkins, Joe B. Mandeville, Friedrich M. Cavagna
Abstract: Injectable aqueous composition intended for opacifying certain organs with a view to examination by X-rays. This composition is based on liposomes containing, encapsulated thereein, an aqueous solution of an iodinated opacifying agent. The ratio between the weight of iodine encapsulated by the liposomes and the weight of the lipids from which their membrane is formed is not lower than 1.5 mg/mg.
Type:
Grant
Filed:
May 12, 1995
Date of Patent:
May 6, 1997
Assignee:
Bracco S.p.A.
Inventors:
Michel Schneider, Herv e Tournier, Bernard Lamy
Abstract: The (6S) stereoisomer of folinic acid is obtained in high optical purity by salification of (R,S) folinic acid with di- or polyamines and subsequent selective crystallization of the desired diasteromeric salt.
Type:
Grant
Filed:
June 1, 1995
Date of Patent:
February 4, 1997
Assignee:
Bracco S.p.A.
Inventors:
Giorgio Ripa, Rodolfo Piva, Ernst Fekder
Abstract: Diagnostic compositions particularly useful for NMR imaging of the gastrointestinal tract, comprise physiologically acceptable aqueous suspensions of insoluble salts of lanthanides, buffered, if required, at a pH value between 6.0 and 8.5 and which are, if required, formulated with appropriate insoluble organic or inorganic additives and/or with dispersing agents, suspending agents or viscosity-enhancing agents. These compositions are capable of increasing the value of the r.sub.2 /r.sub.1 ratio, in which r.sub.1 and r.sub.2 are the longitudinal and transversal relaxivities of the protons of the surrounding water, thus permittting the production of clear images which have negative contrast and which lack artefacts of metallic type.